Extracted from this filing and checked against the source text.
Debt Financings
SEC 8-K Item 2.03/2.04
confidence 0.95
BIOGEN INC. incurred term loan of $1.5 billion unsecured term loan facility with JPMorgan Chase Bank, N.A. at Term SOFR subject to a floor of 0.00% per annum plus an applicable margin rangin maturing Tranche A: 364 days after Funding Date; Tranche B: 3 years after Funding Date.
- Instrument
- term loan
- Principal
- $1.5 billion unsecured term loan facility
- Counterparty
- JPMorgan Chase Bank, N.A.
- Rate
- Term SOFR subject to a floor of 0.00% per annum plus an applicable margin rangin
- Maturity
- Tranche A: 364 days after Funding Date; Tranche B: 3 years after Funding Date
- Event
- incurrence
Exact text from the filing
On August 28, 2023, Biogen Inc. (the “ Company ”) entered into a Credit Agreement with JPMorgan Chase Bank, N.A. (“ JPMorgan ”), as Administrative Agent, and the lenders party thereto (the “ Credit Agreement ”). The Credit Agreement provides for a $1.5 billion unsecured term loan facility, comprised of a $750 million 364-day tranche (“ Tranche A ”) and a $750 million three-year tranche (“ Tranche B ” and collectively, the “ Term Facility ”).
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
BIOGEN INC. entered into Credit Agreement with JPMorgan Chase Bank, N.A., as Administrative Agent, and the lenders party thereto valued at $1.5 billion unsecured term loan facility (effective 2023-08-28).
- Action
- entry
- Agreement
- credit facility
- Counterparty
- JPMorgan Chase Bank, N.A., as Administrative Agent, and the lenders party thereto
- Value
- $1.5 billion unsecured term loan facility
- Effective
- 2023-08-28
Exact text from the filing
On August 28, 2023, Biogen Inc. (the “ Company ”) entered into a Credit Agreement with JPMorgan Chase Bank, N.A. (“ JPMorgan ”), as Administrative Agent, and the lenders party thereto (the “ Credit Agreement ”). The Credit Agreement provides for a $1.5 billion unsecured term loan facility
View on SEC.gov